Vol. 22/No. 24 | Oncology Live®

January 19, 2022

Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.

January 07, 2022

The immune checkpoint TIM-3 is shaping up to be a viable target for designing therapies for patients with non–small cell lung cancer and other malignancies.

January 06, 2022

The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.

January 05, 2022

Early efficacy data in a phase 1 trial of the agent now known as nivolumab were not enough to convince Julie Brahmer, MD, MSc, about the potential of the investigative agent.

January 04, 2022

Maurie Markman, MD, shares how evidence strongly supports that approaches to cancer prevention have little chance of success unless those being targeted are willing to listen to, and ultimately trust, the recommendations being made by members of the scientific community.

December 17, 2021

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs placebo as a postnephrectomy adjuvant therapy in patients with renal cell carcinoma at intermediate-high or high risk of recurrence, and in those who are M1 with no evidence of disease.

December 17, 2021

Treatment options for patients with Waldeström macroglobulinemia are often derived from those devel-oped for patients with multiple myeloma and other low-grade lymphomas.